from Julie Killingsworth reported in youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
BY
deadly street drug had infiltrated the country
@yancyk You are an Illicit Manufactured Fentanyl Historian. Thank you! It’s so important we show proof they all knew a new, highly potent, and extremely deadly street drug had infiltrated the country well before OxyContin was approved. It was only a few years between the OxyContin and Suboxone approvals. Once Suboxone was fast-tracked and approved under the Orphan Drug Act in 2002, the alleged OxyContin Epidemic started being reported by
c)Seth Harp: How CIA Propped Up Afghan Drug Trade
·Page 51 @ (BY MR. HOFFMAN) Do you consider yourself to be or do you hold yourself out as a marketing
expert?
ANSWER: I hold myself as somebody knowledgeable
about the marketing of OxyContin. •
QUESTION: Okay. And other than the 2009 article, which we’re going to talk about in a moment, have you published on the topics of either pharmaceutical marketing of the marketing of OxyContin at any other
point in time?
Page 52 chronic renal insufficiency, so those are common medical problems. I’ve been a prescriber of buprenorphine since 2003, so that’s 16 years now, and about 20 percent of my practice is taking care
of patients with opioid use disorder.
오
Okay. If you can estimate, approximately
how many patients do you see per day?
I would see between 16 and 20 patients a day.
the @supportprop cohort
@BarryMeier Meier glorified the OG Suboxone aggressive overprescriber
OxyContin saves lives
@supportprop member #DrArtVanZee in his Painkiller fiction. How can a prescription drug become an epidemic in a few short years? It can’t. Suboxone Peddlers manufactured the OxyContin Epidemic.
Meier deceptively omitted that Van Zee has been aggressively prescribing #Suboxone to 20% of his patients since 2003 and never prescribed OxyContin. How could Van Zee be an expert in the marketing of a pharmaceutical he’s never prescribed to any of his patients? His OxyContin Marketing publication was initially rejected due to a lack of evidence.
The Prince of Pork Rep. Hal Rogers (PDMP) made sure it was published. Being knowledgeable about a topic does not make someone an Expert. I would absolutely call #DrArtVanZee an expert on deceptive marketing of Suboxone after 16 years of aggressively overprescribing to his unsuspecting (now toothless and hooked if alive) patients.
He should have been in the prison cell next to #ReckittBenckiserGroup #Indivior Chief Marketing Strategist Shaun Thaxter for criminal lying about the safety of Suboxone. The crimes Van Zee committed were worse than Thaxter’s.
He concealed that he was prescribing a highly addictive and dangerous Schedule III pharmaceutical while trying to get another Schedule III pharmaceutical prescribed as needed, recalled.
@supportpro Members Art Van Zee, Stephen Gelfand, and Pete Jackson petitioned with their organization, Advocates For The Reform of Prescription Opioids (ARPO). APRO was deactivated, becoming PROP to have OxyContin recalled while aggressively prescribing Suboxone. We know for a fact that Pete Jackson’s daughter was never prescribed OxyContin by a physician. They will never be held accountable, weaponizing Deception by Omission, destroying the lives of pain patients.
Oklahoma Opioid Epidemic: Deposition Testimony
Art Van Zee Deposition :
https://drive.google.com/file/d/1oRj1MdXTfY6PMyJwScjFseOnEwCfMI7Y/view?usp=drivesdk
ARPO Van Zee, Pete Jackson, Stephen Gelfand OxyContin recall petition :
https://drive.google.com/file/d/19KFW_ebyjY43CsS5sEdnyK-BrbN49zhI/view?usp=drivesdk
“..Understanding the roles of different socioeconomic groups that participate
in poppy cultivation is critical for developing effective and sustainable interventions. As William Byrd and Doris Buddenberg noted, the varying levels of household dependency on opium and different ways they benefit from the crop imply “that there is diversity in households’ responses to shocks like elimination of opium poppy cultivation.”91 Counternarcotics efforts, such
as crop eradication, have had unintended effects, including local economic contraction and increased poverty. Coercive measures have also resulted in poppy cultivation being pushed to other geographic areas, or even intensified. According to some analysts, such measures have increased support for the Taliban and other anti-government elements.92 Counternarcotics programs that ignore local variations and do not account for the reasons why certain groups participate in poppy cultivation run the risk of being ineffective..”
william bryd, phd
or counterproductive.93
ARPO Open Secrets :
https://opencorporates.com/companies/us_fl/N11000001961
Here is a list of every video the zealots have made with live links that cannot be scrubbed from this document. This gives everyone an idea of their HUBRIS. They catalog their lies, believing the millions of people with horrific, incurable bodily afflictions they knowingly harmed would bother to call them out. I bothered, and so did all the amazing researchers in the pain community, including you, Yancy.
https://drive.google.com/file/d/1K1mbcO40wtZRxE6tSawXpDoKUa9I2K8p/view?usp=drivesdk
ARPO petitions to lawmakers :
https://drive.google.com/file/d/18YN6yoUoZ4XGu4ahArI1yMYqXD7JP_Gu/view?usp=drivesdk
OR SEND
TO CASH APP:$docnorm
ZELLE 3135103378
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!
FOR NOW, YOU ARE WITHIN
THE NORMS
REFERENCES:
Briefing Document: Opioid Litigation – Key Themes and So- Called Expert Opinions
This briefing document summarizes key themes and important facts derived from the provided deposition excerpts, focusing on the perspectives of two experts: Jason Beaman, D.O., and Adriane Fugh-Berman, M.D., in the context of Oklahoma’s lawsuit against pharmaceutical companies regarding the opioid epidemic.
I. Expert Criteria and Methodology for Medical Record Review (Jason Beaman, D.O.)
Dr. Jason Beaman, a pain management physician and specialist in addiction psychiatry, was involved in developing criteria for reviewing medical records related to opioid prescriptions for litigation purposes.
- Development of Criteria: The set of three criteria used for medical record review was developed in June or July of 2018 specifically for this litigation to “provide the objective review of the medical records.” (Beaman, p. 114)
- Collaborators: Dr. Beaman collaborated with Dr. Clauw (pain management physician), Dr. Mazloomdoost (pain management physician), and Dr. Kolodny (addiction psychiatry specialist) in establishing these criteria. (Beaman, pp. 111-112)
- Specific Input: While all three collaborators were involved, Dr. Beaman could not pinpoint specific conditions or criteria recommended or excluded by any single individual. (Beaman, pp. 111-112)
- Sickle Cell Anemia Addition: Sickle cell anemia was added to the criteria in the fall of 2018, likely at the suggestion of Dr. Mazloomdoost, and was agreed upon by the other physicians. (Beaman, p. 113)
- Basis for Expertise and Opinion Formation:Dr. Beaman’s expertise stems from “frequent review of documentation and education and materials.” (Beaman, p. 114)
- He acknowledged relying on the 2016 CDC guidelines, which “list 90 MME, along with several specialty organizations.” (Beaman, p. 114)
- Crucially, Dr. Beaman’s opinion that “the majority of physicians in the state of Oklahoma lack the requisite knowledge of the risks and benefits of opioids” was formed only since his involvement in this case. (Beaman, p. 127)
- Information Leading to Opinion on Physician Knowledge Gap:Review of marketing material claiming “opioids are not addicting” and promoting the “concept of pseudoaddiction,” which suggested increasing the dosage of addictive substances if a patient showed signs of addiction (attributing it to untreated pain). (Beaman, pp. 127-128)
- Information regarding pharmaceutical companies paying “medical information dissemination venues, like CME, publications, and medical journals.” (Beaman, p. 128)
- He specifies that the information regarding “pseudoaddiction” and giving more substance to addicted patients was seen in marketing material by Cephalon. (Beaman, p. 130)
- Limitations on Dr. Beaman’s Research and Opinions:He has not interviewed physicians in Oklahoma regarding information received from opioid manufacturers as part of this case. (Beaman, p. 128)
- He has not conducted formal research on the extent to which Oklahoma physicians have been influenced by pharmaceutical marketing. (Beaman, p. 129)
- He does not plan to offer an opinion on the specific impact of pharmaceutical marketing on Oklahoma physicians’ prescribing habits, “other than to say I believe physicians should not be interacting with pharmaceutical representatives on a regular basis.” (Beaman, p. 134-135)
- He will not offer an opinion on the “number or percentage of physicians in the state of Oklahoma who lack the full, complete and accurate knowledge as to the risks and benefits of opioids.” (Beaman, p. 135)
- He has not formally collected data from Oklahoma physicians or patients regarding marketing influence or their experiences with opioid prescriptions. (Beaman, pp. 135-136)
- Patient Overdose Experience: Dr. Beaman has “had numerous conversations with patients in my career, about their experience in being prescribed opioid medications.” (Beaman, p. 136) As a consult psychiatrist at OSU Medical Center from July 2015 until approximately March 2018, he “often, I would say almost daily, evaluated patients that had overdosed on opioid medications that had been prescribed by their physicians.” (Beaman, pp. 136-137)
- Application of Criteria to Specific Prescriptions:The review focused on outpatient-filled prescriptions, not medications administered during hospitalization. (Beaman, p. 202)
- No contact was made with physicians in the sample to clarify missing information from medical records. (Beaman, p. 203)
- If a prescription was made for one of the listed diagnoses (e.g., post-cervical and lumbar laminectomy, spinal cord injuries, spastic neuropathic pain, sickle cell anemia, etc.), it was “deemed to be not medically unnecessary,” regardless of other criteria. (Beaman, pp. 203-204)
- Dr. Beaman is not an expert in treating many of the specific conditions listed in the criteria. (Beaman, pp. 204-206)
- He states that none of his own opioid prescriptions during his career would have met his criteria for being “medically unnecessary.” (Beaman, p. 207)
- He acknowledges that opioids can be appropriate for post-surgical acute pain and sometimes for post-C-section pain. (Beaman, pp. 209-210)
- His opinion is that “you should not give 90 MME to an opioid-naive individual” for post-surgical acute pain, and while not an absolute, it would be “rare” for a non-opioid-naive individual. (Beaman, p. 210-211)
- Actiq/Fentora Review: Out of 245 Actiq or Fentora prescriptions referenced in the petition, Dr. Beaman’s team reviewed only three. All three of these were found “not medically unnecessary.” (Beaman, p. 212, 222) He did not personally review the other 242 and would only extrapolate an opinion on them based on the larger sample. (Beaman, pp. 220-222) Actiq and Fentora are “approved for cancer-related breakthrough pain.” (Beaman, p. 221)
II. Expert Opinion on Pharmaceutical Marketing (Adriane Fugh-Berman, M.D.)
Dr. Adriane Fugh-Berman, an expert in prescription drug marketing, testified regarding the influence of pharmaceutical marketing.
- Awareness of Defendants: Dr. Fugh-Berman was aware of most defendants (Purdue, Johnson & Johnson/Janssen, Teva/Cephalon) but was “not sure about Actavis.” (Fugh-Berman, p. 13) She stated that Watson makes many generics but could not recall specific opioid products. (Fugh-Berman, p. 14)
- Existence of Opioid Epidemic: While she acknowledges the State’s claim of an opioid epidemic, her attorney clarified that she is not testifying as an epidemiologist, but that the defendants have admitted an opioid epidemic exists. (Fugh-Berman, pp. 15-16)
- Scope of Research on Marketing Data:She has “not analyzed prescription drug marketing data in the State of Oklahoma.” (Fugh-Berman, p. 118)
- She is “not aware of any published studies that have — that have examined general pharmaceutical marketing in the State of Oklahoma.” (Fugh-Berman, p. 118)
- She believes such studies are “not actually necessary” because “there are many research articles that have looked at pharmaceutical marketing practices nationally, and there is no reason to think that those practices would be any different in the State of Oklahoma.” (Fugh-Berman, p. 118)
- Basis for Her Opinions: She relies on:
- National studies and research on prescription drug marketing practices. (Fugh-Berman, p. 119-120)
- “Companies’ own documents, including call notes and including plans for pharmaceutical marketing and there are — and the numbers of call visits, for example, that occurred in the State of Oklahoma.” (Fugh-Berman, p. 120)
- Call Notes Access: She was provided a “subset” of call notes by the State’s lawyers because “there were so many of them,” and at some point, she “actively prevented them from providing me with additional call notes.” (Fugh-Berman, p. 120-121) She does not know what percentage of the total call notes she received. (Fugh-Berman, p. 121)
- Oklahoma-Specific Marketing Tactics:She stated that “national information would not exclude Oklahoma and is relevant to Oklahoma.” (Fugh-Berman, p. 137)
- She has not specifically included other information about opioid marketing in Oklahoma in her report, nor has she done research to determine if there were specific marketing tactics used by defendants in Oklahoma. (Fugh-Berman, p. 137)
- She finds such research “unnecessary, given the information from the call notes of the drug reps.” (Fugh-Berman, p. 137)
- Eric Wayman’s Statement: She references Eric Wayman, the Oklahoma sales manager, who stated that “the total prescription level is highly correlated to call activity.” (Fugh-Berman, p. 136) She has not spoken to or interviewed Mr. Wayman, and her knowledge of his beliefs is based solely on his deposition. (Fugh-Berman, p. 136)
III. Inter-Expert Alignment and Discrepancies
- Marketing Influence: Dr. Beaman’s formation of opinion on physicians’ knowledge gaps is directly tied to his review of marketing materials, specifically mentioning Cephalon and the “pseudoaddiction” concept. This aligns with Dr. Fugh-Berman’s general area of expertise regarding the influence of pharmaceutical marketing.
- Oklahoma Specificity: A notable discrepancy is in the necessity of Oklahoma-specific marketing data. Dr. Beaman has not done formal research on marketing influence in Oklahoma. Dr. Fugh-Berman asserts that national marketing data is sufficient and Oklahoma-specific research is “unnecessary” given available call notes, implying a belief that national patterns hold true locally.
- Scope of Expert Opinion: Both experts demonstrate limitations in the scope of their direct, primary research for the case. Dr. Beaman does not offer specific percentages of influenced physicians or medically unnecessary prescriptions at the manufacturer/drug level, while Dr. Fugh-Berman relies on general trends and provided documents rather than independent, state-specific data collection.
